MetaVia Inc. (MTVA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

MetaVia Inc. (MTVA) closed at USD 1.36 on 2026-10-14, a change of -87.3 % over the past year, with a market capitalization of USD 9.03M.

MetaVia Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

MetaVia Inc. key figures

Previous close

USD 1.36 (2026-10-14)

1-year change

-87.3 %

Market cap

USD 9.03M

Enterprise value

USD -3.43M

P/E ratio (trailing)

-0.39

P/E ratio (forward)

n/a

EPS (trailing)

-3.55

EPS (forward)

n/a

PEG ratio

n/a

Price to book

1.32

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.36

Employees

8

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About MetaVia Inc.

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for MetaVia Inc. and compare it with other stocks.